Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Lubomir Sokol, MD, PhD, Kristy L. Richards, PhD, MD, Samir Parekh, MD, Rebecca Elstrom, MD, Ashraf Z. Badros, MD, Igor Espinoza-Delgado, MD, Michael J. Schell, PhD, Amy Kimball, MD, PhD, Mary Beth Tombes, RN, Ellen Shrader, Heidi Sankala, PhD, Domenico Coppola, MD, Maciej Kmieciak, PhD, Daniel Sullivan, MD, John D. Roberts, MD, Steven Grant, MD

Blood (2011) 118 (21): 779.

https://doi.org/10.1182/blood.V118.21.779.779

Published: 2011

Journal Articles

Final Results From a Phase II Trial of Triapine® Plus Fludarabine for Adults with Aggressive Myeloproliferative Disorders

Michael A McDevitt, MD, PhD, Robert L Dilley, Keith W. Pratz, MD, B. Douglas Smith, MD, Alison R. Moliterno, MD, Yun Yen, MD, PhD, Lisa Malick, RN, Steven D. Gore, MD, Richard J. Jones, Jaroslaw P. Maciejewski, MD, PhD, Igor Espinoza-Delgado, MD, Judith E. Karp, MD

Blood (2011) 118 (21): 1755.

https://doi.org/10.1182/blood.V118.21.1755.1755

Published: 2011

Journal Articles

Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210- BCR/ABL Expressing Cell Lines.

Rachel E. Rau, MD, Emily McIntyre, Scott H. Kaufmann, MD, PhD, Igor Espinoza-Delgado, MD, Judith Karp, Patrick Brown, MD

Blood (2009) 114 (22): 2742.

https://doi.org/10.1182/blood.V114.22.2742.2742

Published: 2009

Journal Articles

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

Blood (2009) 114 (13): 2764–2773.

https://doi.org/10.1182/blood-2009-02-203547

Published: 2009

Includes: Supplemental data

Journal Articles

Preliminary Results from a Phase II Trial of Triapine Plus Fludarabine for Adults with Aggressive Myeloproliferative Disorders

Michael A McDevitt, Judith E. Karp, Yun Yen, MD, PhD, Jaroslaw Maciejewski, Igor Espinoza-Delgado

Blood (2008) 112 (11): 2811.

https://doi.org/10.1182/blood.V112.11.2811.2811

Published: 2008

Journal Articles

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

Steven Grant, MD, Sarah Kolla, Leonardo Andres Sirulnik, MD, PhD, Geoffrey Shapiro, Jeffrey Supko, Brenda Cooper, Edward Perkins, Viswanathan Ramakrishnan, Igor Espinoza-Delgado, MD, M B Tombes, John D Roberts

Blood (2008) 112 (11): 2986.

https://doi.org/10.1182/blood.V112.11.2986.2986

Published: 2008

Journal Articles

Phase I Trial of Vorinostat Combined with Cytarabine and Etoposide in Patients (pts) with Advanced Acute Leukemia and High-Risk Myelodysplastic Syndromes

Ivana Gojo, MD, Ming T. Tan, PhD, Ken Shiozawa, MD, PhD, Takeo Nakanishi, PhD, Angelika M Burger, PhD, Colette L Burgess, BS, Merrill J Egorin, MD, Maria R. Baer, MD, Michael L Tidwell, RN, CRNP, Rakesh Srivastava, PhD, France Carrier, PhD, Angela Scardina, RN, Igor Espinoza-Delgado, MD, Douglas D. Ross, MD, PhD

Blood (2008) 112 (11): 4011.

https://doi.org/10.1182/blood.V112.11.4011.4011

Published: 2008

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study.

Mark Kirschbaum, MD, Leslie Popplewell, Auayporn P. Nademanee, Vinod Pullarkat, Maria Delioukina, Jasmine M. Zain, Deron Matsuoka, Bernadette Pulone, Paul Frankel, Igor Espinoza-Delgado, MD, Stephen J. Forman, David Gandara, Edward Newman

Blood (2008) 112 (11): 1564.

https://doi.org/10.1182/blood.V112.11.1564.1564

Published: 2008

Journal Articles

A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium

Lewis R. Silverman, MD, Amit Verma, Rosalie Odchimar-Reissig, Amanda LeBlanc, Vesna Najfeld, Janice Gabrilove, Luis Isola, Igor Espinoza-Delgado, MD, James Zwiebel

Blood (2008) 112 (11): 3656.

https://doi.org/10.1182/blood.V112.11.3656.3656

Published: 2008

Journal Articles

High Response Rates in Acute Steroid Refractory Graft-Versus-Host Disease (GVHD) Following Combined Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-2 (IL-2) Blockade.

Ramaprasad Srinivasan, MD, PhD, Nancy Geller, PhD, Colleen Dorrance, MD, Igor Espinoza-Delgado, MD, A. John Barrett, MD, Yoshiyuki Takahashi, MD, PhD, Richard W. Childs, MD

Blood (2005) 106 (11): 1801.

https://doi.org/10.1182/blood.V106.11.1801.1801

Published: 2005

Journal Articles

Evaluation of Three Different Cyclosporine-Based Graft Versus Host Disease (GVHD) Prophylaxis Regimens Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).

Ramaprasad Srinivasan, MD, PhD, Nancy Geller, PhD, Sakti Chakrabarti, MD, Igor Espinoza-Delgado, MD, Teresa Donohue, Susan Leitman, MD, Charles D. Bolan, MD, Elizabeth J. Read, MD, John A. Barrett, MD, Richard W. Childs, MD

Blood (2004) 104 (11): 1236.

https://doi.org/10.1182/blood.V104.11.1236.1236

Published: 2004

Journal Articles

The Antineoplastic Agent Bryostatin-1 Induces Proinflammatory Cytokine Production in Human Monocytes: Synergy With Interleukin-2 and Modulation of Interleukin-2Rγ Chain Expression

Maria Carla Bosco, Sandra Rottschafer, Lynn S. Taylor, John R. Ortaldo, Dan L. Longo, Igor Espinoza-Delgado

Blood (1997) 89 (9): 3402–3411.

https://doi.org/10.1182/blood.V89.9.3402

Published: 1997

NARROW

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Final Results From a Phase II Trial of Triapine® Plus Fludarabine for Adults with Aggressive Myeloproliferative Disorders

Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210- BCR/ABL Expressing Cell Lines.

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

Preliminary Results from a Phase II Trial of Triapine Plus Fludarabine for Adults with Aggressive Myeloproliferative Disorders

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

Phase I Trial of Vorinostat Combined with Cytarabine and Etoposide in Patients (pts) with Advanced Acute Leukemia and High-Risk Myelodysplastic Syndromes

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study.

A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium

High Response Rates in Acute Steroid Refractory Graft-Versus-Host Disease (GVHD) Following Combined Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-2 (IL-2) Blockade.

Evaluation of Three Different Cyclosporine-Based Graft Versus Host Disease (GVHD) Prophylaxis Regimens Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).

The Antineoplastic Agent Bryostatin-1 Induces Proinflammatory Cytokine Production in Human Monocytes: Synergy With Interleukin-2 and Modulation of Interleukin-2Rγ Chain Expression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only